Drug Profile
Igrelimogene litadenorepvec - TILT Biotherapeutics
Alternative Names: Ad5/3-E2F-d24-hTNFa-IRES-hIL2; TILT 123Latest Information Update: 16 Apr 2024
Price :
$50
*
At a glance
- Originator TILT Biotherapeutics
- Developer MSD BV; TILT Biotherapeutics
- Class Antineoplastics; Gene therapies; Immunotherapies; Oncolytic viruses
- Mechanism of Action Cell death stimulants; Immunologic cytotoxicity; Interleukin-2 expression stimulants; Tumour necrosis factor alpha stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Solid tumours
Most Recent Events
- 10 Apr 2024 Efficacy and adverse events data from phase I trial in Ovarian cancer (Combination therapy, Second-line therapy or greater) released by TILT Biotherapeutics
- 20 Mar 2024 Phase-I clinical trials in Non-small cell lung cancer (Combination therapy, Second-line therapy or greater) in USA (Parenteral) (NCT06125197)
- 08 Dec 2023 Efficacy and adverse events data from a phase I trial in Malignant melanoma released by TILT Biotherapeutics